"Biotech in the Balance" - Dr. Jeremy Levin, Chairperson of Ovid Therapeutics
Dr. Jeremy Levin, chairperson of Ovid Therapeutics, joins I Don't Care with Dr. Kevin Stevenson to discuss the industry's "covenant with the patient," the complexities of drug pricing and the role of PBMs, and whether America can maintain its biotech leadership as China prioritizes the field strategically.
This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.
Promoted content from I Don't Care on MarketScale.
Key takeaways
Dr. Jeremy Levin is the Chair of Ovid Therapeutics.
Free workspace
Turn your Healthcare expertise into content.
Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.
Few industries have changed—and saved—more lives than biotechnology and pharmaceuticals. Yet few industries face as much public distrust.
That contradiction is at the heart of this conversation with Dr. Jeremy Levin, chairperson of Ovid Therapeutics, on I Don't Care with Dr. Kevin Stevenson.
The covenant with the patient
Levin has spent his career at the highest levels of biotech and pharma, and he doesn't shy away from where the industry has gone wrong. His assessment is straightforward: somewhere along the way, the industry lost sight of what he calls its "covenant with the patient."
The conversation explores why drug pricing is far more complicated than the number patients see at the pharmacy counter, the role PBMs and other intermediaries play, and why rebuilding public trust must begin with transparency and putting patients back at the center.
America's biotech leadership at risk
Levin also addresses a much larger question: Is America at risk of losing its leadership in biotechnology? With China treating biotech as a strategic national priority, the stakes extend well beyond healthcare economics to American innovation, competitiveness and national security.
The question isn't whether extraordinary advances in gene therapy, cell therapy, AI and diseases like Alzheimer's are coming. It's whether they will happen here or abroad.
Part of this channel
I Don't Care
Candid healthcare leadership conversations with Kevin Stevenson
Your experts belong here
Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.
Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.
About the author
